ARTICLE | Company News
Amgen gets Priority Review for ivabradine
August 28, 2014 12:58 AM UTC
FDA accepted and granted Priority Review to an NDA from Amgen Inc. (NASDAQ:AMGN) for ivabradine to treat chronic heart failure (CHF). The selective If channel inhibitor is already marketed as Procoral...